Genetics/Genomics News

Editor’s Note: This is part three of a three-part Healio Exclusive series on the development and use of AI to improve clinical outcomes in cardiovascular medicine and considerations for regulatory labeling and patient privacy .

Editor’s Note: This is part two of a three-part Healio Exclusive series on the development and use of AI to improve clinical outcomes in cardiovascular medicine and considerations for regulatory labeling and patient privacy.

Editor’s Note: This is part one of a three-part Healio Exclusive series on the development and use of AI to improve clinical outcomes in cardiovascular medicine and considerations for regulatory labeling and patient privacy .

In this Healio video exclusive, Sana M. Al-Khatib, MD, professor of medicine at Duke University School of Medicine, discusses barriers to developing cardiovascular digital health solutions for women.

The American Heart Association Scientific Sessions will be held in-person only in Chicago from Nov. 16 to 18 and will feature eight late-breaking science sessions during the 3-day meeting.

Congenital heart disease-related deaths from 2005 to 2019 were more prevalent among Black vs. white infants, a gap that persisted year after year, a speaker reported at the American Academy of Pediatrics National Conference & Exhibition.

In patients with persistent chylomicronemia, plozasiran, a small interfering RNA therapy, was associated with lower triglyceride levels and reduced risk for pancreatitis, researchers reported at the European Society of Cardiology Congress.

Many recently recalled cardiovascular devices did not undergo premarket testing prior to FDA approval, and postmarket studies of the devices were slow and infrequent, researchers reported.

A platelet reactivity score that identifies people with a hyperreactive platelet phenotype can be used to determine those who might be at elevated risk for a cardiovascular event, researchers reported in Nature Communications.